PubMed · 3141993
AL-1576, an aldose reductase inhibitor (ARI), did not prevent the decrease of norepinephrine turnover in diabetic rats.
Abstract
ONO-2235 [(E)-3-carboxymethyl-5-[(2E)-2-methyl-3-phenyl-propenylidene]rhodanine], an ARI, was reported to prevent significantly the decrease of norepinephrine (NE) turnover in three tissues of streptozotocin (STZ)-diabetic rats (1). To examine whether the partial restoration of NE turnover by ONO-2235 is related to its ARI activity, the effect of another ARI, AL-1576 [spiro(2,7-difluoro-9H-fluoren-9, 4'-imidazoline)-2'5'-dione], on NE turnover in STZ rats was investigated. STZ caused an accumulation of sorbitol in the lens and decreased NE turnover in interscapular brown adipose tissue (IBAT), heart and pancreas. AL-1576 totally prevented the accumulation of sorbitol in the lens but had no effect on the decreased NE turnover in all three tissues. These results suggest that the partial prevention of NE turnover decrease by ONO-2235 may not have been mediated by its ARI activity.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
T T Yen, R W Fuller, C L Broderick, S K Hemrick-Luecke, K W Perry. 1988. AL-1576, an aldose reductase inhibitor (ARI), did not prevent the decrease of norepinephrine turnover in diabetic rats.. https://pubmed.health/record/pubmed%3A3141993/al-1576-an-aldose-reductase-inhibitor-ari-did-not-prevent-the-decrease-of-norepinephrine-turnover-in
Citations retain the original authors and DOI and include this site’s record URL. If this discovery service contributed to your research, you can also cite PubMed Health by Indiciae: BibTeX · RIS.